Diabetes Self-Management Blog

Following upon the recent conclusion from an analysis of multiple studies that diabetes drug rosiglitazone (brand name Avandia) may increase heart attack risk (see “Type 2 Drug Avandia Linked to Increased Risk of Heart Attacks”), the U.S. Food and Drug Administration (FDA) has launched its own analysis of data abut the drug. Last week, a statement from a member of Congress indicated that the preliminary results of the FDA’s evaluation show a similar magnitude of heart attack risk.

The FDA confirmed that its own analysis of multiple studies (called a meta-analysis), found heart attack rates similar to the meta-analysis published recently in The New England Journal of Medicine (NEJM). However, the FDA also stated that it has conflicting data from various studies and is therefore continuing to evaluate the results of an ongoing trial of rosiglitazone. This trial, called the RECORD trial, is a large-scale study specifically designed to look at the cardiovascular effects of rosiglitazone. Its complete results, however, will not be available until 2009.

An editorial published last week in the British medical journal The Lancet cited two previous large-scale studies that did not show any statistically significant increases in heart attack risk in people taking rosigitazone. It advised that doctors and people taking rosiglitazone “can reasonably await the results of RECORD” and should not jump to conclusions about rosiglitazone’s safety based on the results of the NEJM meta-analysis. However, the RECORD trial may be in danger of not being able to continue because some of the trial’s 4,450 participants have recently dropped out because of safety concerns. While rosiglitazone manufacturer GlaxoSmithKline did not reveal how many people had dropped out of the study, the company and the independent research committees overseeing the study have expressed concern about how to retain participants so the trial can be completed.

POST A COMMENT       
  

Comments
  1. There are no comments at this time.


Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.


Type 2 Diabetes
Metformin Study Currently Recruiting (08/19/14)
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)
Dispelling the Myths of Insulin Therapy (08/01/14)

Oral Medicines
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)
New SGLT Drugs Coming (07/23/14)
Metformin More Effective in African-Americans (07/10/14)

Diabetes Research
Pistachios Offer Protection for People With Diabetes (08/29/14)
New Approach for Neuropathy Pain? (08/18/14)
Metformin Study Currently Recruiting (08/19/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)

Diabetes News
Pistachios Offer Protection for People With Diabetes (08/29/14)
New Approach for Neuropathy Pain? (08/18/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)
Shift Work Tied to Increased Type 2 Diabetes Risk (07/31/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.